Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Activase
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 72 results found since Jan 2013.
Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke
To evaluate the efficacy of tirofiban administered at different time points within 24 hours of intravenous thrombolysis with alteplase in acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - January 14, 2019 Category: Neurology Authors: Jin Liu, Qiuyan Shi, Yuan Sun, Jingyuan He, Bin Yang, Chunyang Zhang, Rui Guo Source Type: research
Even Faster Door-to-Alteplase Times and Associated Outcomes in Acute Ischemic Stroke
We report a single-center, retrospective assessment of the safety and efficacy of alteplase treatment within 45 minutes. Methods: Five hundred and eighty-six patients were treated with alteplase in our emergency departments (EDs) between January 2014 and October 2016; 368 patients were included for analysis.
Source: Journal of Stroke and Cerebrovascular Diseases - October 9, 2019 Category: Neurology Authors: Sarah Jung, Jamie M. Rosini, Jason T. Nomura, Richard J. Caplan, Jonathan Raser-Schramm Source Type: research
Redefining Early Neurological Improvement After Reperfusion Therapy in Stroke
Background and Purpose: Early neurologic improvement (ENI) in patients treated with alteplase has been shown to correlate with functional outcome. However, the definition of ENI remains controversial and has varied across studies. We hypothesized that ENI defined as a percentage change in the National Institute of Health Stroke Scale (NIHSS) score (percent change NIHSS score) at 24-hours would better correlate with favorable outcomes at 3 months than ENI defined as the change in NIHSS score (delta NIHSS score) at 24 hours.
Source: Journal of Stroke and Cerebrovascular Diseases - December 15, 2019 Category: Neurology Authors: Shashank Agarwal, Shawna Cutting, Brian Mac Grory, Tina Burton, Mahesh Jayaraman, Ryan McTaggart, Michael Reznik, Erica Scher, Andrew D. Chang, Jennifer Frontera, Aaron Lord, Sara Rostanski, Koto Ishida, Jose Torres, Karen Furie, Shadi Yaghi Source Type: research
Familiarization with Contact Aspiration using Non-Penetrating of the Thrombus (CANP) Technique as the Initial Procedure for Acute Ischemic Stroke
Thrombectomy, along with intravenous alteplase, had been the standard medical care to achieve rapid and complete reperfusion for acute ischemic stroke.1 Many devices and techniques had been developed and devised, respectively, to achieve rapid and complete reperfusion. Thrombectomy includes stent retriever thrombectomy, with or without aspiration assistance, and contact aspiration (CA), mainly a direct aspiration first-pass technique (ADAPT). Kang et al. reported CA using a catheter with an inner diameter (I.D.) of 0.041 in.
Source: Journal of Stroke and Cerebrovascular Diseases - September 3, 2021 Category: Neurology Authors: Hiroaki Neki, Takehiro Katano, Takuma Maeda, Aoto Shibata, Hiroyuki Komine, Yuichiro Kikkawa Source Type: research
Caught in Action – Evolving Emergent Large Vessel Occlusion and Collateral Failure During Alteplase Infusion for Acute Ischemic Stroke
Published reports of acute deterioration during alteplase infusion for acute ischemic stroke due to development of partial to complete large vessel occlusion and collateral failure are sparce.
Source: Journal of Stroke and Cerebrovascular Diseases - October 27, 2021 Category: Neurology Authors: Peter S.W. Park, Helen M. Dewey, Philip M.C. Choi Tags: Case Report Source Type: research
Safety of early antiplatelet administration in patients with acute ischemic stroke treated with alteplase (SEAPT-24)
This study aimed to examine the safety of early antiplatelet therapy administration within the first 24 h after alteplase.
Source: Journal of Stroke and Cerebrovascular Diseases - November 5, 2022 Category: Neurology Authors: Drew A. Wells, Lyndsey K. Davis, Omar Saeed, G. Morgan Jones, Cheran Elangovan, Andrei V. Alexandrov, Balaji Krishnaiah, Katherine L. March Source Type: research
Validation of the Telestroke Mimic Score in Mayo Clinic Population
Telestroke consultations enable hospital providers to administer intravenous (IV) alteplase to patients who would otherwise not receive it due to lack of an in-hospital stroke team. However, up to 30% of acute stroke patient evaluations are deemed to be stroke mimics. Mimics present a challenge with the limitations of a virtual neurological exam. The administration of IV alteplase in these patients is not without risk. With the cost and risk associated with IV alteplase, there are both ethical and practical incentives to avoid administering alteplase to a patient manifesting a stroke-mimic.
Source: Journal of Stroke and Cerebrovascular Diseases - August 10, 2021 Category: Neurology Authors: Rachel Carlin, Nan Zhang, Bart M. Demaerschalk Source Type: research
Fatal Intraperitoneal Bleeding after Intravenous Administration of Tissue Plasminogen Activator
We report a case of acute ischemic stroke, which developed fatal intraperitoneal bleeding after intravenous administration of alteplase. An 86-year-old woman developed acute infarction of the right middle cerebral artery during admission for chronic heart failure. Two days before the stroke, liver biopsy was performed; the result was benign. Although rivaroxaban was prescribed for atrial fibrillation, the rivaroxaban had been discontinued for liver biopsy until the time when she developed the stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - April 18, 2015 Category: Neurology Authors: Chise Anan, Masahiro Oomura, Tomoaki Saeki, Toshimasa Ikeda, Chikako Sato, Kentaro Yamada Tags: Case Report Source Type: research
Follow-up Imaging After Thrombolysis: FIAT, A Randomized Trial
Current protocols for treatment of acute ischemic stroke with intravenous thrombolytics, such as alteplase (tPA) and tenecteplase (tNK), recommend the completion of a routine non-contrast head CT at 24 hours post treatment to evaluate for hemorrhage prior to the initiation of antiplatelet therapy for secondary stroke prevention. This guideline was instituted because it had been part of the protocol in the NINDS multicenter randomized placebo-controlled trial that showed the benefit of IV thrombolytics within 3 hours of stroke onset.
Source: Journal of Stroke and Cerebrovascular Diseases - April 15, 2023 Category: Neurology Authors: Burton Tabaac, Leah Dickstein, Kristen Gurnea, Argye E. Hillis Source Type: research
Successful Intra-arterial Thrombolysis in a Patient with an Intracranial Meningioma
We report a case of a 78-year-old man who was seen in our emergency department within 2 hours from sudden onset of aphasia, right-sided hemiplegia, hypoesthesia, and homonymous hemianopsia. The National Institutes of Health Stroke Scale (NIHSS) score at admission was 20. Intra-arterial thrombolysis was performed with administration of .3 mg/kg of alteplase combined with mechanical thrombectomy. At discharge, his NIHSS score was 1, and after 90 days, his modified Rankin score was 1. To our knowledge, this is the first report of intra-arterial thrombolysis in a patient with acute ischemic stroke with an intracranial tumor.
Source: Journal of Stroke and Cerebrovascular Diseases - July 8, 2013 Category: Neurology Authors: Robson F. Baiense, Agessandro Abrahão, Irapuá F. Ricarte, Thiago G. Fukuda, Ricardo A. Oliveira, Gisele S. Silva, Maristela Costa, Manoel J. Teixeira Tags: Case Reports Source Type: research
Long-term survival after alteplase —3 year results from the IST-3 trial
We report the effect of intravenous alteplase on long-term survival after ischaemic stroke of participants in the Third International Stroke Trial (IST-3).
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: William Whiteley, Eivind Berge, Joanna Wardlaw, Richard Lindley, Peter Sandercock, IST-3 Collaborative Group Source Type: research
What is the Price of the Potential for a Meaningful Recovery following Intracerebral Hemorrhage?
In this issue of the Journal of Stroke and Cerebrovascular Diseases, Vardanyan and colleagues report on the cost-utility of minimally invasive surgery (MIS) with thrombolysis for spontaneous intracerebral hemorrhage (ICH) from the perspective of the United Kingdom (UK) National Health Service (NHS)1 using data from the Minimally Invasive Surgery Plus Alteplase in Intracerebral Hemorrhage Evacuation (MISTIE III) trial2 and the UK Sentinel Stroke National Audit Programme (SSNAP).3 The economic evaluation revealed that the incremental cost-effectiveness ratio for MIS with thrombolysis fell significantly above the UK's Nationa...
Source: Journal of Stroke and Cerebrovascular Diseases - July 27, 2021 Category: Neurology Authors: Lourdes R. Carhuapoma, Avni Kapadia, Henry A. Glick, Daniel F. Hanley Source Type: research
Sustainability of Intravenous Alteplase Administration via Telephone-Based Consult: Data from a US Health System
Despite multiple advances in management over the last few decades, acute ischemic stroke (AIS) is still associated with high morbidity and mortality.1 Intravenous alteplase (IV tPA) was shown to be efficacious and safe for AIS about a quarter century ago2 and remains the only Food and Drug Administration-approved medication for this indication. Though ideal, stroke neurologists may not be available in-person to decide whether to administer tPA to an AIS patient.
Source: Journal of Stroke and Cerebrovascular Diseases - January 27, 2022 Category: Neurology Authors: Sarah E. Nelson, Eric Aldrich, Brenda Johnson, Susan Groman, Richard E. Thompson, Victor Urrutia Source Type: research
Thromboelastographic Changes in Patients Experiencing an Acute Ischemic Stroke and Receiving Alteplase
Source: Journal of Stroke and Cerebrovascular Diseases - January 21, 2014 Category: Neurology Authors: A. Shaun Rowe, Christal L. Greene, Carolyn C. Snider, Roger C. Carroll, Brian F. Wiseman, Jennifer M. Henry, J. Russell Langdon, Robert M. Craft Tags: Original Articles Source Type: research
Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study
Approximately 10 years have passed since intravenous (IV) recombinant tissue plasminogen activator therapy was approved in Japan. The aim of this retrospective study was to identify the effectiveness and safety of IV alteplase therapy with the Japanese original dose around Hiroshima via consideration of the patients' backgrounds, examination findings, and outcomes.
Source: Journal of Stroke and Cerebrovascular Diseases - September 7, 2015 Category: Neurology Authors: Shiro Aoki, Naohisa Hosomi, Yoshimasa Sueda, Tomoyuki Kono, Kazuhiro Takamatsu, Hideo Ohyama, Tsuyoshi Torii, Takeshi Kitamura, Eiichi Nomura, Koichi Noda, Toshiho Ohtsuki, Masayasu Matsumoto, HARP Registry Study Group Source Type: research
